A rash diagnosis: Gemcitabine-associated pseudocellulitis.
Identifieur interne : 000834 ( Main/Exploration ); précédent : 000833; suivant : 000835A rash diagnosis: Gemcitabine-associated pseudocellulitis.
Auteurs : Christopher Strouse [États-Unis] ; Narendranath Epperla [États-Unis]Source :
- Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [ 1477-092X ] ; 2017.
Descripteurs français
- KwdFr :
- Abstention thérapeutique, Adulte d'âge moyen, Adénocarcinome (anatomopathologie), Adénocarcinome (traitement médicamenteux), Antinéoplasiques antimétabolites (effets indésirables), Antinéoplasiques antimétabolites (usage thérapeutique), Biopsie, Cellulite sous-cutanée (), Cellulite sous-cutanée (diagnostic), Cellulite sous-cutanée (physiopathologie), Cellulite sous-cutanée (sang), Créatinine (sang), Diagnostic différentiel, Désoxycytidine (analogues et dérivés), Désoxycytidine (effets indésirables), Désoxycytidine (usage thérapeutique), Exanthème (), Exanthème (anatomopathologie), Exanthème (diagnostic), Exanthème (sang), Femelle, Humains, Hyperleucocytose (sang), Jambe, Tumeurs du pancréas (anatomopathologie), Tumeurs du pancréas (traitement médicamenteux), Érythème (), Érythème (anatomopathologie), Érythème (diagnostic), Érythème (sang).
- MESH :
- analogues et dérivés : Désoxycytidine.
- anatomopathologie : Adénocarcinome, Exanthème, Tumeurs du pancréas, Érythème.
- diagnostic : Cellulite sous-cutanée, Exanthème, Érythème.
- effets indésirables : Antinéoplasiques antimétabolites, Désoxycytidine.
- physiopathologie : Cellulite sous-cutanée.
- sang : Cellulite sous-cutanée, Créatinine, Exanthème, Hyperleucocytose, Érythème.
- traitement médicamenteux : Adénocarcinome, Tumeurs du pancréas.
- usage thérapeutique : Antinéoplasiques antimétabolites, Désoxycytidine.
- Abstention thérapeutique, Adulte d'âge moyen, Biopsie, Cellulite sous-cutanée, Diagnostic différentiel, Exanthème, Femelle, Humains, Jambe, Érythème.
English descriptors
- KwdEn :
- Adenocarcinoma (drug therapy), Adenocarcinoma (pathology), Antimetabolites, Antineoplastic (adverse effects), Antimetabolites, Antineoplastic (therapeutic use), Biopsy, Cellulitis (blood), Cellulitis (chemically induced), Cellulitis (diagnosis), Cellulitis (physiopathology), Creatinine (blood), Deoxycytidine (adverse effects), Deoxycytidine (analogs & derivatives), Deoxycytidine (therapeutic use), Diagnosis, Differential, Erythema (blood), Erythema (chemically induced), Erythema (diagnosis), Erythema (pathology), Exanthema (blood), Exanthema (chemically induced), Exanthema (diagnosis), Exanthema (pathology), Female, Humans, Leg, Leukocytosis (blood), Middle Aged, Pancreatic Neoplasms (drug therapy), Pancreatic Neoplasms (pathology), Withholding Treatment.
- MESH :
- chemical , adverse effects : Antimetabolites, Antineoplastic, Deoxycytidine.
- chemical , analogs & derivatives : Deoxycytidine.
- blood : Cellulitis, Creatinine, Erythema, Exanthema, Leukocytosis.
- chemically induced : Cellulitis, Erythema, Exanthema.
- diagnosis : Cellulitis, Erythema, Exanthema.
- drug therapy : Adenocarcinoma, Pancreatic Neoplasms.
- pathology : Adenocarcinoma, Erythema, Exanthema, Pancreatic Neoplasms.
- physiopathology : Cellulitis.
- chemical , therapeutic use : Antimetabolites, Antineoplastic, Deoxycytidine.
- Biopsy, Diagnosis, Differential, Female, Humans, Leg, Middle Aged, Withholding Treatment.
Abstract
Gemcitabine is an antitumor agent with broad clinical application. The most common cutaneous toxicities are mild rash and pruritus; however, a severe 'pseudocellulitis' rash, which resembles infectious cellulitis in clinical presentation, has increasingly been recognized as a rare complication of this agent. Though the specific pathophysiology related to this condition is not clear, it has been observed to occur primarily in regions of significant lymphadenopathy or prior radiation exposure typically after 24-48 h following administration of gemcitabine. It is a self-limiting reaction, with most cases resolving within two to seven days of onset without any specific treatment for the rash. Treatment with gemcitabine may be safely continued in patients with this complication, though recurrence of the rash is common following repeated doses. We report a case of biopsy confirmed gemcitabine associated pseudocellulitis in a patient treated for metastatic pancreatic adenocarcinoma. Knowledge of this complication is important to avoid unwarranted hospitalizations and antibiotic use in patients treated with gemcitabine.
DOI: 10.1177/1078155216635852
PubMed: 26946530
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000959
- to stream PubMed, to step Curation: 000959
- to stream PubMed, to step Checkpoint: 000959
- to stream Ncbi, to step Merge: 007F84
- to stream Ncbi, to step Curation: 007F84
- to stream Ncbi, to step Checkpoint: 007F84
- to stream Main, to step Merge: 000835
- to stream Main, to step Curation: 000834
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A rash diagnosis: Gemcitabine-associated pseudocellulitis.</title><author><name sortKey="Strouse, Christopher" sort="Strouse, Christopher" uniqKey="Strouse C" first="Christopher" last="Strouse">Christopher Strouse</name><affiliation wicri:level="2"><nlm:affiliation>1 Department of Internal Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>1 Department of Internal Medicine, Medical College of Wisconsin, Milwaukee, WI</wicri:regionArea><placeName><region type="state">Wisconsin</region></placeName></affiliation></author><author><name sortKey="Epperla, Narendranath" sort="Epperla, Narendranath" uniqKey="Epperla N" first="Narendranath" last="Epperla">Narendranath Epperla</name><affiliation wicri:level="2"><nlm:affiliation>2 Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>2 Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI</wicri:regionArea><placeName><region type="state">Wisconsin</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:26946530</idno><idno type="pmid">26946530</idno><idno type="doi">10.1177/1078155216635852</idno><idno type="wicri:Area/PubMed/Corpus">000959</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000959</idno><idno type="wicri:Area/PubMed/Curation">000959</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000959</idno><idno type="wicri:Area/PubMed/Checkpoint">000959</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000959</idno><idno type="wicri:Area/Ncbi/Merge">007F84</idno><idno type="wicri:Area/Ncbi/Curation">007F84</idno><idno type="wicri:Area/Ncbi/Checkpoint">007F84</idno><idno type="wicri:Area/Main/Merge">000835</idno><idno type="wicri:Area/Main/Curation">000834</idno><idno type="wicri:Area/Main/Exploration">000834</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A rash diagnosis: Gemcitabine-associated pseudocellulitis.</title><author><name sortKey="Strouse, Christopher" sort="Strouse, Christopher" uniqKey="Strouse C" first="Christopher" last="Strouse">Christopher Strouse</name><affiliation wicri:level="2"><nlm:affiliation>1 Department of Internal Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>1 Department of Internal Medicine, Medical College of Wisconsin, Milwaukee, WI</wicri:regionArea><placeName><region type="state">Wisconsin</region></placeName></affiliation></author><author><name sortKey="Epperla, Narendranath" sort="Epperla, Narendranath" uniqKey="Epperla N" first="Narendranath" last="Epperla">Narendranath Epperla</name><affiliation wicri:level="2"><nlm:affiliation>2 Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>2 Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI</wicri:regionArea><placeName><region type="state">Wisconsin</region></placeName></affiliation></author></analytic><series><title level="j">Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners</title><idno type="eISSN">1477-092X</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenocarcinoma (drug therapy)</term><term>Adenocarcinoma (pathology)</term><term>Antimetabolites, Antineoplastic (adverse effects)</term><term>Antimetabolites, Antineoplastic (therapeutic use)</term><term>Biopsy</term><term>Cellulitis (blood)</term><term>Cellulitis (chemically induced)</term><term>Cellulitis (diagnosis)</term><term>Cellulitis (physiopathology)</term><term>Creatinine (blood)</term><term>Deoxycytidine (adverse effects)</term><term>Deoxycytidine (analogs & derivatives)</term><term>Deoxycytidine (therapeutic use)</term><term>Diagnosis, Differential</term><term>Erythema (blood)</term><term>Erythema (chemically induced)</term><term>Erythema (diagnosis)</term><term>Erythema (pathology)</term><term>Exanthema (blood)</term><term>Exanthema (chemically induced)</term><term>Exanthema (diagnosis)</term><term>Exanthema (pathology)</term><term>Female</term><term>Humans</term><term>Leg</term><term>Leukocytosis (blood)</term><term>Middle Aged</term><term>Pancreatic Neoplasms (drug therapy)</term><term>Pancreatic Neoplasms (pathology)</term><term>Withholding Treatment</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Abstention thérapeutique</term><term>Adulte d'âge moyen</term><term>Adénocarcinome (anatomopathologie)</term><term>Adénocarcinome (traitement médicamenteux)</term><term>Antinéoplasiques antimétabolites (effets indésirables)</term><term>Antinéoplasiques antimétabolites (usage thérapeutique)</term><term>Biopsie</term><term>Cellulite sous-cutanée ()</term><term>Cellulite sous-cutanée (diagnostic)</term><term>Cellulite sous-cutanée (physiopathologie)</term><term>Cellulite sous-cutanée (sang)</term><term>Créatinine (sang)</term><term>Diagnostic différentiel</term><term>Désoxycytidine (analogues et dérivés)</term><term>Désoxycytidine (effets indésirables)</term><term>Désoxycytidine (usage thérapeutique)</term><term>Exanthème ()</term><term>Exanthème (anatomopathologie)</term><term>Exanthème (diagnostic)</term><term>Exanthème (sang)</term><term>Femelle</term><term>Humains</term><term>Hyperleucocytose (sang)</term><term>Jambe</term><term>Tumeurs du pancréas (anatomopathologie)</term><term>Tumeurs du pancréas (traitement médicamenteux)</term><term>Érythème ()</term><term>Érythème (anatomopathologie)</term><term>Érythème (diagnostic)</term><term>Érythème (sang)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antimetabolites, Antineoplastic</term><term>Deoxycytidine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Deoxycytidine</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Désoxycytidine</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Adénocarcinome</term><term>Exanthème</term><term>Tumeurs du pancréas</term><term>Érythème</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Cellulitis</term><term>Creatinine</term><term>Erythema</term><term>Exanthema</term><term>Leukocytosis</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Cellulitis</term><term>Erythema</term><term>Exanthema</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Cellulitis</term><term>Erythema</term><term>Exanthema</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Cellulite sous-cutanée</term><term>Exanthème</term><term>Érythème</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Adenocarcinoma</term><term>Pancreatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antinéoplasiques antimétabolites</term><term>Désoxycytidine</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Adenocarcinoma</term><term>Erythema</term><term>Exanthema</term><term>Pancreatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Cellulite sous-cutanée</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Cellulitis</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Cellulite sous-cutanée</term><term>Créatinine</term><term>Exanthème</term><term>Hyperleucocytose</term><term>Érythème</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antimetabolites, Antineoplastic</term><term>Deoxycytidine</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Adénocarcinome</term><term>Tumeurs du pancréas</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques antimétabolites</term><term>Désoxycytidine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Biopsy</term><term>Diagnosis, Differential</term><term>Female</term><term>Humans</term><term>Leg</term><term>Middle Aged</term><term>Withholding Treatment</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Abstention thérapeutique</term><term>Adulte d'âge moyen</term><term>Biopsie</term><term>Cellulite sous-cutanée</term><term>Diagnostic différentiel</term><term>Exanthème</term><term>Femelle</term><term>Humains</term><term>Jambe</term><term>Érythème</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Gemcitabine is an antitumor agent with broad clinical application. The most common cutaneous toxicities are mild rash and pruritus; however, a severe 'pseudocellulitis' rash, which resembles infectious cellulitis in clinical presentation, has increasingly been recognized as a rare complication of this agent. Though the specific pathophysiology related to this condition is not clear, it has been observed to occur primarily in regions of significant lymphadenopathy or prior radiation exposure typically after 24-48 h following administration of gemcitabine. It is a self-limiting reaction, with most cases resolving within two to seven days of onset without any specific treatment for the rash. Treatment with gemcitabine may be safely continued in patients with this complication, though recurrence of the rash is common following repeated doses. We report a case of biopsy confirmed gemcitabine associated pseudocellulitis in a patient treated for metastatic pancreatic adenocarcinoma. Knowledge of this complication is important to avoid unwarranted hospitalizations and antibiotic use in patients treated with gemcitabine.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Wisconsin</li></region></list><tree><country name="États-Unis"><region name="Wisconsin"><name sortKey="Strouse, Christopher" sort="Strouse, Christopher" uniqKey="Strouse C" first="Christopher" last="Strouse">Christopher Strouse</name></region><name sortKey="Epperla, Narendranath" sort="Epperla, Narendranath" uniqKey="Epperla N" first="Narendranath" last="Epperla">Narendranath Epperla</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000834 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000834 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26946530
|texte= A rash diagnosis: Gemcitabine-associated pseudocellulitis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26946530" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |